Heterocyclic compounds

A pharmaceutical composition comprising a compound of the formula

• wherein
• A is aryl or heteroaryl, said aryl and said heteroaryl being optionally substituted by one to three substituents independently selected from the group consisting of halogen, benzyloxy, heteroaryl-C1-6 alkoxy, C1-6 alkyl, C1-6 alkoxy and halo C1-6 alkoxy, or said aryl and said heteroaryl being optionally substituted by C1-6 alkylenedioxy;
• X is —N(R1)(R2) or —N+(R1)(R2)(R11);
• with (a) R1 and R2 are, independently selected from hydrogen, C1-6 alkyl, C3-6 alkenyl, C3-6 alkynyl, hydroxy C2-6 alkyl, C1-6 alkoxy C2-6 alkyl, C3-7 cycloakyl, C3-7 cycloalkyl C1-6 alkyl, C7-10 bicycloalkyl, phenyl C1-3 alkyl, heteroaryl C1-3 alkyl, heterocyclyl or heterocyclyl C1-6 alkyl, in which the cycloalkyl of said C3-7 cycloalkyl and said C3-7 cycloalkyl C1-6 alkyl, the phenyl of said phenyl C1-3, alkyl, the heteroaryl of said heteroaryl C1-3 alkyl and the heterocyclyl of said heterocyclyl and said heterocyclyl C1-6 alkyl are optionally substituted by one to three substituents independently selected from the group consisting of Rd;
• or
• (b) R1 and R2, together with the nitrogen atom to which they are attached, form a heterocyclyl optionally substituted by one to three substituents independently selected from the group consisting of Rd, and one of the ring carbon atoms of said heterocyclyl formed by R1 and R2 being optionally replaced with a carbonyl group;
• and/or
• one of the ring carbon atoms of the heterocyclyl formed by R1 and R2 may be a ring carbon atom of another ring which is C3-7 cycloalkyl or heterocyclyl, one or two ring carbon atoms of said another ring being optionally replaced by a carbonyl group, and said another ring being optionally substituted by C1-6 alkyl;
• R3 and R4 are, independently hydrogen, hydroxy, C1-6 alkyl,
• C1-6 alkoxy, C3-7 cycloalkyl, C3-7 cycloalkyl C1-6 alkyl, C1-6 alkoxycarbonyl, carboxyl, carbamoyl, mono or di-C1-6 alkyl substituted carbamoyl, C1-6 alkoxycarbonyloxy, mono or di-C1-6 alkyl substituted aminocarbonyloxy, hydroxy-C1-6 alkyl, C1-6 alkoxy-C1-6 alkyl, halogen or halo C1-6 alkyl;
• or
• R3 and R4, together with the carbon atom to which they are attached, form C3-7 cycloalkyl or heterocyclyl optionally substituted by one to three substituents independently selected from the group consisting of C1-4 alkyl, halo C1-4 alkyl and halogen;
• Y is C(O) or S(O)2;
• R5 and R6 are independently hydrogen, C1-6 alkyl or C3-7 cycloalkyl, said C1-6 alkyl and said C3-7 cycloalkyl being optionally substituted by one to three substituents independently selected from the group consisting of amino, hydroxy, carboxyl, carbamoyl, mono or di-C1-6 alkyl substituted carbamoyl and C1-6 alkoxycarbonyl;
• or
• R5 and R6, together with the carbon atom to which they are attached, form C3-7 cycloalkyl or heterocyclyl;
• R7, R8, R9 and R10 are independently hydrogen, C1-6 alkyl or C3-7 cycloalkyl, said C1-6 alkyl being optionally substituted by one to three substituents independently selected from the group consisting of hydroxy, C1-6 alkoxy, carboxyl, carbamoyl, mono or di-C1-6 alkyl substituted carbamoyl and C1-6 alkoxycarbonyl, aryl and heteroaryl, in which said aryl and said heteroaryl are optionally substituted by one to three substituents independently selected from the group consisting of halogen, C1-6 alkyl, halo C1-6 alkyl, C1-6alkoxy and halo C1-6 alkoxy,
• R11 is C1-6 alkyl;
• Rd is hydroxy, cyano, NRaRb, halogen, C1-6 alkyl, halo C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkoxy, C1-6 alkoxy C1-6 alkyl, C3-7 cycloalkyl, C1-6 alkoxycarbonyl, acyl, —C(O)NRaRb, —NRaC(O)—Rb, —NRa—C((O))—ORb, —NRa—C(O)—NRb, —NRa—SO2—Rb, NRa—SO2—NRbRc, —OC(O)NRaRb, —OC(O)ORa, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl, C1-6 alkylthio, phenyl, phenyl C1-3 alkyl, heteroaryl, heteroaryl C1-3 alkyl or and heterocyclyl, and the phenyl of said phenyl and said phenyl C1-3 alkyl, the heteroaryl of said heteroaryl and said heteroaryl C1-3 alkyl, and the heterocyclyl being optionally substituted by one to three substituents independently selected from the group consisting of hydroxy, cyano, NRaRb, halogen, C1-6 alkyl, halo C1-6 alkyl, hydroxy C1-6 alkyl, C1-6 alkoxycarbonyl, acyl, —C(O)NRaRb, —NRa—C(O)—Rb, —NRa—C(O)—ORb, —NRa—C(O)—NRb, —NRa—SO2—Rb, —NRa—SO2—NRbRc, —OC(O)NRaRb, —OC(O)ORa, C1-6 alkylsulfonyl, C1-6 alkylsulfinyl and C1-6 alkylthio, and one or two ring carbon atoms of the heterocyclyl being optionally replaced with a carbonyl group;
• Ra, Rb and Rc are independently hydrogen or C1-6 alkyl;
• n is an integer of 0 to 3;
• m is an integer of 0 to 3;
• m+n is an integer of 1 to 5;
• wherein, unless otherwise indicated,
• aryl is phenyl or naphthyl;
• heterocyclyl is non-aromatic mono- or bi-cyclic radicals of four to nine ring atoms in which one to three ring atoms are heteroatoms independently selected from N, O and S(O)n (where n is an integer from 0 to 2), the remaining ring atoms being C;
• heteroaryl is a monocyclic or bicyclic radical of 5 to 10 ring atoms having one to three ring heteroatoms independently selected from N, O, and S, the remaining ring atoms being C;
• acyl is R—C(O)—, in which R is C1-6 alkyl, halo C1-6 alkyl, C3-7 cycloalkyl or C3-7 cycloalkyl C1-6 alkyl;
• or a prodrug or pharmaceutically acceptable salt thereof
• and a pharmaceutically acceptable excipient.